TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00950352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
Study: NCT00700752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: silicone hydrogel contact lens
Study: NCT03761953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin Injection
Description: single 1200mg infusion of IV oritavancin.
Study: NCT03138850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus standard bite block
Description: Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YX mandibular advancement bite block
Description: Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow High flow nasal cannula
Description: Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
Study: NCT00649519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
Description: 10/20mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® Capsules 10 mg/20 mg
Description: 10/20mg, single dose fasting
Study: NCT00584103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta P Experimental
Description: Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
Study: NCT02345434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative letter
Description: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
Study: NCT00279500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus 16 Retinal Stimulation System
Description: The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
Study: NCT01256619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
Study: NCT04560296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based E-Health Program
Description: Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
Study: NCT00674336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Hydrostatic Pressure Processing
Description: High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
Study: NCT03865407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
Study: NCT01072864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 5 g of walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 20 g of walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 30 g of walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Consumption of 40 g of walnuts.
Study: NCT04459299

Intervention type: DEVICE
Intervention: Robotic-PCI (CorPath GRX System)
Description: Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
Study: NCT01524211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® t-Branch
Description: The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Arch Branch
Description: The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
Study: NCT02467595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.15 mg kg-1
Description: Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 0.3 mg kg-1
Description: Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 mcg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 2.5 mg kg-1 was injected at I.V. line to patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
Study: NCT04479501

Intervention type: OTHER
Intervention: Asthma exacerbation related hospitalization
Description: Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
Study: NCT04181203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Salvage radiotherapy (SRT)
Description: The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (SRT)
Description: The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinising Hormone Releasing Hormone agonist (LHRHa)
Description: Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinising Hormone Releasing Hormone agonist (LHRHa)
Description: Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
Study: NCT01401088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial drainage implant
Description: Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
Study: NCT02703116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use BI
Description: Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Intervention
Description: Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
Study: NCT02183545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: single rising doses given as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given as tablet (matching placebo of BI 1060469)
Study: NCT02052960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CetuGEX™
Description: 60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Study: NCT03879668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eIPOS
Description: Electronic version of IPOS
Study: NCT02126644

Intervention type: DRUG
Group type: OTHER
Intervention: 70% glycolic acid
Study: NCT02917486

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample
Study: NCT01571882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit
Description: 1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit
Description: 2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)
Description: 3- Intervention with active control product (1,6 g of plant sterol/ day)
Study: NCT02805907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04560296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual self-management and follow up with doctors/nurse
Description: usual self-management and follow up with doctors/nurse as planned in the community nurse post.
Study: NCT03448081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriene
Description: Calcipotriene ointment (0.005%)
Study: NCT03059303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 75 mg
Description: Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 75 mg
Description: Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 75 mg
Description: Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 75 mg
Description: Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
Study: NCT03448081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriene
Description: Calcipotriene ointment (0.005%)
Study: NCT04330547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic administration
Description: * Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Folavit (folic acid, 0.4 mg)
Study: NCT04425031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low oxygenation target
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High oxygenation target
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Study: NCT04797936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNO 1030
Description: Imupret 25 drops х 6 times per day for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
Study: NCT00575601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIMVASTATIN
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SIMVASTATIN
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
Study: NCT00897676

Intervention type: DRUG
Group type: OTHER
Intervention: Exendin-(9-39)
Description: 100-500pmol/kg/min

Intervention type: DRUG
Group type: OTHER
Intervention: Exendin-(9-39)
Description: 100-500pmol/kg/min

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo (0.9% NaCl)

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo (0.9% NaCl)
Study: NCT04461587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: see previous entries
Study: NCT03750357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Relief v 2.0
Description: To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
Study: NCT00751023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400 mg daily for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets daily for 4 weeks
Study: NCT01707316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin 100 mg
Description: Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin 100 mg
Description: Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin 100 mg
Description: Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin 300 mg
Description: Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin 300 mg
Description: Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin 300 mg
Description: Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo
Description: Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
Study: NCT03199365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Undergo TSSC intervention sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Undergo TSSC intervention sessions
Study: NCT03537729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient Cues
Description: Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salient Cues
Description: Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Education
Description: Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
Study: NCT00864227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation
Description: The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis
Description: GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days.
Study: NCT04416776

Intervention type: DRUG
Intervention: Strabismus diagnostic system.
Description: An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.